Drug Approval | January 03, 2022
Emcure to launch oral Covid-19 drug soon
A toll-free helpline to be set up to help doctors and patients
A toll-free helpline to be set up to help doctors and patients
G42 Healthcare and AstraZeneca will work closely together to explore real-world evidence and conduct clinical trials through IROS – the first-of-its-kind Contract Research Organization (CRO) in the UAE
Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS-CoV-2
In India, healthcare has become one of the fastest-growing economic sectors which comprise hospitals, pharma companies, medical equipment and devices, medical tourism, health insurance, clinical trials etc
The Subject Expert Committee (SEC), on Covid-19 of the Central Drugs Standard Control Organisation (CDSCO) on Monday recommended granting permission to manufacture and market anti-Covid pill molnupiravir for restricted emergency use
It plans to deliver over 300 million doses to the Indian government
The company will market it under the brand name Molflu
The company has developed the API in house at its R&D center in Hyderabad
The Home Healthcare market is expected to be US $ 14.2 by 2025
The authorization provides an additional treatment option against the Covid-19 virus in the form of a pill that can be taken orally
Subscribe To Our Newsletter & Stay Updated
